The Investor
31 Oct 2025, 15:03
AbbVie Reports Strong Q3 2025 Results with 9% Revenue Growth, Lifts Full-Year Outlook
AbbVie (NYSE: ABBV) posted third-quarter 2025 revenues of $15.78 billion, up 9.1% year-over-year (8.4% operationally), driven by continued strength in immunology and neuroscience portfolios. GAAP EPS was $0.10, while adjusted EPS stood at $1.86, down 38%, reflecting a $1.50 per-share impact from acquired IPR&D and milestones expense.
The immunology portfolio led performance with $7.89 billion in revenue (+11.9%), fueled by Skyrizi ($4.71 billion, +46.8%) and Rinvoq ($2.18 billion, +35.3%), offsetting Humira’s expected decline (-55%).
Neuroscience sales rose 20.2% to $2.84 billion, supported by Vraylar ($934 million), Botox Therapeutic ($985 million), and migraine treatments Ubrelvy and Qulipta (combined $642 million).
The oncology segment slipped 0.3% to $1.68 billion, while aesthetics declined 3.7% to $1.19 billion, as Botox Cosmetic and Juvederm faced softer demand.
AbbVie’s adjusted operating margin was 30.9%, with a 24.5% adjusted tax rate, and the company reaffirmed its long-term EPS growth target of 5–7% through 2029.
Citing strong business momentum, AbbVie raised its full-year adjusted EPS guidance to $10.61–$10.65 (from $10.38–$10.58) and announced a 5.5% dividend increase for 2026, payable in February. CEO Robert A. Michael highlighted progress in innovation and pipeline development as key drivers of long-term growth.
AbbVie (NYSE: ABBV) posted third-quarter 2025 revenues of $15.78 billion, up 9.1% year-over-year (8.4% operationally), driven by continued strength in immunology and neuroscience portfolios. GAAP EPS was $0.10, while adjusted EPS stood at $1.86, down 38%, reflecting a $1.50 per-share impact from acquired IPR&D and milestones expense.
The immunology portfolio led performance with $7.89 billion in revenue (+11.9%), fueled by Skyrizi ($4.71 billion, +46.8%) and Rinvoq ($2.18 billion, +35.3%), offsetting Humira’s expected decline (-55%).
Neuroscience sales rose 20.2% to $2.84 billion, supported by Vraylar ($934 million), Botox Therapeutic ($985 million), and migraine treatments Ubrelvy and Qulipta (combined $642 million).
The oncology segment slipped 0.3% to $1.68 billion, while aesthetics declined 3.7% to $1.19 billion, as Botox Cosmetic and Juvederm faced softer demand.
AbbVie’s adjusted operating margin was 30.9%, with a 24.5% adjusted tax rate, and the company reaffirmed its long-term EPS growth target of 5–7% through 2029.
Citing strong business momentum, AbbVie raised its full-year adjusted EPS guidance to $10.61–$10.65 (from $10.38–$10.58) and announced a 5.5% dividend increase for 2026, payable in February. CEO Robert A. Michael highlighted progress in innovation and pipeline development as key drivers of long-term growth.